ArticleCureus2025
From Velocity to Acceleration: A Perspective on Age-Related Visual Field Progression in Glaucoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The conventional evaluation of visual field (VF) progression in glaucoma often relies on linear regression to estimate the rate of decline, focusing on velocity (dB/year). However, this approach may underestimate future progression, particularly in elderly patients. This editorial highlights the importance of incorporating acceleration (dB/year²) into clinical assessments of VF loss. Using physiological and pathological models, we demonstrate that VF sensitivity decline is inherently nonlinear with age. A cubic model illustrates age-related sensitivity loss in healthy eyes, while a quadratic model captures the interaction between disease duration and baseline age in glaucomatous eyes. These models emphasize that progression accelerates over time and suggest that individualized treatment intensity should consider not only the current rate of VF decline but also its likely acceleration based on patient age and disease course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.